कंपनी का अवलोकन
Aclaris Therapeutics, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the discovery and development of novel molecular product candidates specifically targeting immuno-inflammatory diseases within the United States. The company functions within the Healthcare sector and the Biotechnology industry, classifications that define its reliance on extensive research and development cycles rather than immediate product commercialization. This organization maintains a workforce of 69 employees and holds a total market capitalization of $494.04 million, reflecting its status as a mid-sized entity in the public markets. Its trailing twelve-month revenue stands at $7.83 million, a figure that, when combined with its market cap, indicates a significant market premium relative to its current sales generation. Such a valuation structure is characteristic of clinical-stage firms where investor capital is priced against the potential future success of the pipeline rather than current cash flows, placing the company in a high-risk, high-reward position typical of early-stage biotechnology development.
वित्तीय स्वास्थ्य
Aclaris Therapeutics reported a net income of negative $64,923,000 for the trailing twelve months, while its revenue remained at $7.83 million and its EBITDA stood at negative $74,035,000. The substantial disparity between the modest revenue of $7.83 million and the heavy net loss reveals a cost structure dominated by operational expenditures and research costs that far exceed current sales, a pattern standard for companies in the clinical development phase. The company's free cash flow is negative $30,631,876, which signifies that the firm is consuming cash reserves to fund its operations and development activities rather than generating liquidity from its business. Despite this cash burn, the company holds a cash balance of $90.75 million against a debt load of only $2.12 million, indicating a balance sheet that is primarily funded by equity and cash rather than leverage. The debt-to-equity ratio of 2.05 suggests a capital structure where debt obligations are present but relatively minor compared to the equity base, while the current ratio of 3.36 demonstrates strong short-term liquidity, as the firm holds sufficient current assets to cover its short-term liabilities more than three times over. Furthermore, the return on equity is -50.2% and the return on assets is -24.3%, metrics that reflect the negative impact of ongoing losses on the value generated per unit of capital employed by management. These negative return figures are consistent with a development-stage company where earnings are not yet realized, but they underscore the financial pressure to convert the pipeline into revenue-generating products to stabilize these metrics.
मूल्यांकन आकलन
The trailing P/E ratio is listed as N/A due to the lack of positive earnings, whereas the forward P/E is -5.44, a metric that implies the market is pricing in the expectation of future profitability or is utilizing a negative earnings baseline for projection purposes. The price-to-book ratio stands at 4.77, indicating that the market values the company at nearly five times its book value, which suggests a significant premium assigned to the intangible value of the clinical pipeline and intellectual property. Additionally, the price-to-sales ratio is 63.13 and the EV/EBITDA is -5.45, metrics that highlight the extreme valuation multiple relative to sales volume and the inability to utilize EBITDA as a traditional multiple due to negative earnings. The stock's 52-week trading range spans from a low of $1.05 to a high of $4.89, providing a clear volatility band within which the current price fluctuates based on market sentiment regarding the drug pipeline. The beta value of 0.68 indicates that the stock's price volatility is lower than the broader market benchmark, suggesting it may be less sensitive to general market swings despite its high-risk sector classification. These valuation figures collectively portray an asset that is priced for significant future growth potential rather than current financial performance, a common dynamic for biotechnology firms with promising but unproven product candidates.
Growth & Income
The company's revenue growth year-over-year is -85.9%, while earnings growth is N/A due to the absence of prior year positive earnings for comparison. The contraction in revenue indicates a challenging period for sales or a strategic shift in product lifecycle management, while the lack of positive earnings growth precludes a standard comparison of earnings expansion versus revenue expansion. As the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it retains all available earnings and cash flow to reinvest into research, development, and the expansion of its product pipeline. This reinvestment strategy is essential for a clinical-stage firm that must fund its operations to reach market approval, as there are no interim returns for shareholders to sustain the 0.0% payout ratio. The overall growth and income profile is currently defined by negative revenue momentum and a reliance on external capital or internal cash reserves to fund future growth rather than providing immediate income through dividends or earnings expansion.